Minimal Residual Disease and IGHV-Genes Mutational Status as the Main Predictors of Response to Bendamustine-Rituximab Therapy in Previously Untreated Chronic Lymphocytic Leukemia

Minimal Residual Disease and IGHV-Genes Mutational Status as the Main Predictors of Response to Bendamustine-Rituximab Therapy in Previously Untreated Chronic Lymphocytic Leukemia

Background. In patients with chronic lymphocytic leukemia (CLL) the eradication of minimal residual disease (MRD) is a prognostic factor of overall survival (OS) and progression-free survival (PFS). IGHV mutational status has also independent prognostic value. Aim. To analyse the impact of mutati...

Full description

Saved in:
Bibliographic Details
Main Authors: YuV Mirolyubova, EA Stadnik, VV Strugov, TO Andreeva, TS Nikulina, YuV Virts, PA Butylin, AG Rumyantsev, AYu Zaritskey
Format: Article
Language:Russian
Published: Practical Medicine Publishing House 2018-04-01
Series:Клиническая онкогематология
Subjects:
chronic lymphocytic leukemia
minimal residual disease
bendamustine
rituximab
BR
IGHV
mutational status
Online Access:http://bloodjournal.ru/wp-content/uploads/2018/03/5-1.pdf
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items